Apricus Biosciences Inc ($APRI) - Oversold - views

Apricus Biosciences Inc has hit a technical signal on 3 different technical indicators. APRI is in the Consumer Durables sector. The technical signals indicate that the stock is Oversold right now. The 3 indicators: Commodity Channel Index, Relative Strength Index and the Fast Stochastics were all triggered based on the last closing price of $3.65 on Feb 10.

There is currently one analyst covering the company with a Buy recommendation. The current consensus estimate for quarterly earnings is per share. The analyst covering the company is forecasting earnings of per share. The consensus estimate for next years' earnings is per share, which represents forecast growth of 0.0%.

Over the last 52 weeks, the stock has been trading between $3.23 and $6.10. More recently in the last 4 weeks, the stock has been trading between $3.62 and $5.75. Yesterday the stock traded between $3.62 and $3.77. The stock currently has a PE ratio of 0.0.

Apricus Biosciences Inc is trading -25.8% from its 20-day simple moving average (SMA) of $4.92 and -27.9% from its 50-day SMA and -22.11% from its 200-day SMA. Average daily volume over the last 30 days has been 324,157 shares.

At yesterdays close: the RSI was at 19.2, the CCI was at -325.0 and the Fast Stochastic was at 1.9. APRI closed yesterday at $3.65, on volume of 927,175 shares as compared to an average volume of 324,157 over the last 4 weeks.

Apricus Biosciences, Inc. engages in the design and development of pharmaceutical products and product candidates based on its patented NexACT drug delivery technology. The NexACT drug delivery technology is designed to enhance the delivery of an active drug to improve therapeutic outcomes and reduce systemic side effects that accompany existing oral and injectable medications. The company is also seeking commercialization partnerships for its product, Vitaros, which is approved in Canada for the treatment of erectile dysfunction (ED); and its additional existing clinical and pre-clinical pipeline of product candidates, such as Femprox for female sexual arousal disorder, MycoVa for onychomycosis excluding tinea pedis (nail fungal infection), RayVa for RaynaudÂ’s Syndrome, and PrevOnco for liver cancer. It has compounds in development from pre-clinical through Phase III in the areas of sexual dysfunction, oncology, dermatology, autoimmune, pain, anti-infectives, diabetes, and cosmeceuticals. The company was founded in 1987 and is headquartered in San Diego, California.

Technical Indicators should be used as the starting point for further analysis. These indicators are provided as a guide to help you determine what assets to analyze. The technical indicators used in this article can indicate that an asset is either overbought or oversold, but that indication could be the result of a fundamental or other type of event like an earnings announcement.

To learn more about technical analysis, please refer to our technical analysis primer.